The new facility also facilitates the production of advanced and difficult-to-manufacture solid dosage forms such as tablets and capsules, in addition to the manufacturing of novel CAR-T cell
“There are no FDA-approved treatments currently available to patients diagnosed with molluscum, the majority of whom are children, leaving caregivers to choose between a wait-and-see approach or treatments
The NDA has been accepted for the priority review of selective fibroblast growth factor receptor (FGFR) inhibitor pemigatinib to treat patients with previously treated, locally advanced or metastatic
Health officials have identified MDR gonorrhea, a sexually transmitted bacteria, as an urgent global public health threat, exacerbated by limited diagnostics and treatment options. Each year, according to
Remsima SC is claimed to be the world’s first subcutaneous formulation of infliximab. The EC approval was based on clinical evidence, including results from a study that demonstrated
Under the terms of the agreement, Vor obtains non-exclusive clinical and commercial use rights to MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to develop up to five engineered
Calquence, which is a next-generation selective inhibitor of Bruton’s tyrosine kinase (BTK), binds covalently to BTK to inhibit its activity. The FDA approval was based on data from
AHP is a family of ultra-rare, genetic diseases characterized by debilitating, potentially life-threatening attacks and, for some patients, chronic manifestations that negatively impact daily functioning and quality of
With the closing of the acquisition, Celgene became a wholly-owned subsidiary of BMS. Under the deal, Celgene shareholders secured for each share, 1.00 share of BMS common stock
CNS’ licensing agreement with HPI grants the Company the exclusive right to develop certain patented chemical compounds for use in the treatment of cancer globally. In its agreement
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.